Global Antineoplastic Agents Market Research Report 2022

Market Analysis and Insights: Global Antineoplastic Agents Market
New anti-tumor targets and corresponding new anti-tumor agents or means are: targeting cell signal transduction molecules, including protein tyrosine kinase inhibitors, farnesyltransferase (FTase) inhibitors, MAPK signaling pathway inhibitors, and cell cycle regulators.Targeting neovascularization: neovascularization inhibitors;To reduce the detachment, adhesion and basement membrane degradation of cancer cells: anti-metastasis drugs;Targeting telomerase: telomerase inhibitor;Drug resistance to tumor cells: drug resistance reversal agent;Promoting the mature differentiation of malignant cells: differentiation inducers;Specific killing of cancer cells :(antibody or toxin) directed therapy;Enhance the efficacy of radiotherapy and chemotherapy: tumor treatment sensitizers;Enhance or regulate collective immune function: biological response modulator;For oncogenes and tumor suppressor genes: gene therapy - introduction of wild-type tumor suppressor genes, suicide genes, anti-drug resistance genes and antisense oligonucleotides, tumor genetic engineering tumor bacteria.
The global Antineoplastic Agents market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Chemotherapy accounting for % of the Antineoplastic Agents global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Plant Medicine segment is altered to an % CAGR throughout this forecast period.
China Antineoplastic Agents market size is valued at US$ million in 2021, while the North America and Europe Antineoplastic Agents are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Antineoplastic Agents landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antineoplastic Agents market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antineoplastic Agents market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antineoplastic Agents market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antineoplastic Agents market.
Global Antineoplastic Agents Scope and Market Size
Antineoplastic Agents market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Antineoplastic Agents market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
by Treatment Means
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy (Biologic Therapy)
Others
by Dosage Form
Injection
Tablets
Capsule
Suppository
Granules
Implant
其他
by Nature of the Drug
Pharmaceutical Chemicals
Biological Medicine
Natural Product
Segment by Application
Plant Medicine
Hormone
Platinum Compounds
Metabolism Of Drug Resistance
Targeting Small Molecules
Drugs For Cancer
Antibiotic
Alkylating Agent
Chemoradiotherapy Protectant
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
BMS
MSD
Johnson & Johnson
Pfizer
AstraZeneca
Novartis
Sanofi
Celgene
Roche
Lilly
Bayer
Abraxis
Gilead
Wto-Day Order Pharmaceutical
Sinopharm
Shandong Lvye Pharmaceutical
CTTQ
Jiangsu Hengrui Pharmaceutical
Qilu Pharmaceutical
Baekdu Mountain Pharmaceutical
Baida Pharmaceutical
Jiangsu Haosen Pharmaceutical Group
Hainan Chang'an International Pharmaceutical
Zhejiang Kanglaite Pharmaceutical
Shandong New Era Pharmaceutical
Liaoning Novino Pharmaceutical
Maanshan Fengyuan Pharmaceutical
Meiluo Pharmaceutical
Shandong Luoxin Pharmaceutical Group
Zhejiang Yatai Pharmaceutical
Tesaro (GSK)
Eisai
Biogen Idec
Teva
AbbVie